This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.
Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.
DexCom (DXCM) G6 CGM System Now Available to TRICARE Members
by Zacks Equity Research
The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management
by Zacks Equity Research
DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Masimo's (MASI) New Product Expansion to Boost Patient Outcome
by Zacks Equity Research
Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.
DexCom (DXCM) to Boost Diabetes Management With New Approval
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.
Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario
by Zacks Equity Research
Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation
by Zacks Equity Research
Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.
Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCG
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
DexCom (DXCM) Q4 Earnings Lag Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH
by Urmimala Biswas
Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.
The Markets' Tone: Cautiously Optimistic
by Daniel Laboe
As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Earnings Preview: DexCom (DXCM) Q4 Earnings Expected to Decline
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $435.04, marking a +1.06% move from the previous day.